# Immunologic Effects of Supplemental Monosaccharide and Nucleoside Derivatives in Patients With Inherited Disorders of Glycosylation

> **NCT02511041** · PHASE1 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 2 (actual)

## Conditions studied

- PGM3

## Interventions

- **DRUG:** N-Acetylglucosamine (GlcNAc)
- **DRUG:** Uridine

## Key facts

- **NCT ID:** NCT02511041
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06-30
- **Primary completion:** 2017-01-24
- **Final completion:** 2017-01-24
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02511041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02511041, "Immunologic Effects of Supplemental Monosaccharide and Nucleoside Derivatives in Patients With Inherited Disorders of Glycosylation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02511041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*